Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 7/20 | 0.70 |
| ▸ | DRD2 | P14416 | 4/20 | 0.64 |
| ▸ | DRD3 | P35462 | 4/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701304 | 0.95 | PPARG (0.91) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL5701156 | 0.91 | PPARG (0.83) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL9319380 | 0.86 | PPARG (0.74) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL5701146 | 0.83 | PPARG (0.71) | PPARGDRD4DRD2DRD3ALOX5 | |
| SCHEMBL8740486 | 0.83 | DRD4 (1.00) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL9269749 | 0.81 | DRD4 (0.83) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL5701236 | 0.81 | DRD2 (0.71) | PPARGDRD4DRD2DRD3ALOX5 | |
| SCHEMBL5701143 | 0.81 | PPARG (0.68) | PPARGDRD4DRD2DRD3ALOX5 | |
| SCHEMBL9269886 | 0.80 | DRD4 (0.80) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL9269193 | 0.80 | DRD4 (0.80) | PPARGDRD4DRD2DRD3ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | claimed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | claimed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | claimed |
| EP-1682484-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-26 | — | — | EP | disclosed |
| US-7081465-B2 | Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-25 | — | — | US | disclosed |
| WO-2005042465-A1 | OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-05-12 | — | — | WO | disclosed |
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | disclosed |
| WO-1995029155-A1 | NOVEL ANTITUMOUR COMPOUNDS WITH ANTIMITOTIC ACTIVITY | PHARMACIA AB (SE) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192688-A1 | Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders | APOB, LIPC, FABP3 | PPARG 102/4885DRD4 656/4885DRD2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.